DPP-4 Inhibitor Composition for Vascular Calcification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Vascular calcification contributes to various cardiovascular complications, including hypertension, heart failure, and valvular diseases, and existing treatments are inadequate in effectively inhibiting this process.

Innovation Solution

A composition containing a dipeptidyl peptidase-4 (DPP-4) inhibitor, which can be administered as a pharmaceutical or food component, is used to inhibit the expression or activity of DPP-4, thereby reducing vascular or valvular calcification by targeting the increased DPP-4 levels associated with calcification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If DPP-4 inhibitor is used to inhibit vascular calcification, then calcification is reduced, but existing treatments are inadequate

Engineering Contradiction:

Improveeffectiveness in inhibiting calcificationVSAvoidtreatment adequacy

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the biochemical parameter by introducing a DPP-4 inhibitor that specifically targets the DPP-4 enzyme pathway. This enzyme inhibition alters the metabolic processing of peptides involved in calcification, thereby reducing vascular and valvular calcification where existing treatments failed to achieve sufficient effectiveness.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If DPP-4 inhibitor is administered, then calcification decreases, but the mechanism involves complex enzymatic pathways

Engineering Contradiction:

Improvecalcification reductionVSAvoidenzymatic pathway complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and targets a specific enzyme (DPP-4) from the complex enzymatic pathways involved in calcification. By focusing inhibition on this single key enzyme rather than attempting to modulate multiple pathways simultaneously, the treatment achieves reliable calcification reduction while simplifying the therapeutic approach.

Inventive Principle:

Principle #2Taking out (Extraction)

3Object-generated harmful factors

If DPP-4 expression is increased in calcification models, then calcification is promoted, but inhibition of DPP-4 activity is required

Engineering Contradiction:

Improvecalcification promotion by DPP-4VSAvoidcalcification damage

Core Design Contradiction:

Object-generated harmful factorsVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of DPP-4 enzyme activity (which promotes calcification) into a beneficial therapeutic target. By designing an inhibitor that blocks DPP-4 activity, the treatment transforms the enzyme's calcification-promoting function into a controlled pathway that can be inhibited to prevent calcification damage in vascular and valvular tissues.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The DPP-4 inhibitor effectively decreases calcification in blood vessels and valves, providing a prophylactic and therapeutic solution for vascular or valvular calcification, as demonstrated by its ability to reduce calcification in animal models and patient studies.

Implementation Method 1

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentUS9416196B2Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor

Publication Date: 2016.08.16 THE ASAN FOUND

AI summary

There is provided a composition for prophylaxis or treatment of vascular or valvular calcification including a dipeptidylpeptidase-4 (DPP-4) inhibitor. The DPP-4 according to one exemplary embodiment of the present disclosure is expressed at an increased level when blood vessels and valves are calcified, and the calcification decreases remarkably upon administration of the DPP-4 inhibitor. Therefore, the DPP-4 inhibitor can be useful in treatment or prophylaxis of blood vessels or valves.